In the tumor, this effect was most prominent in the Flt3L+NDV cohort, with significantly higher expression of activation markers (e.g. MHC I/II, CD80, CD40), particularly in cDC1s, suggesting greater-than-additive effect when combining NDV and Flt3L (Fig. 3f). The gene discussed is CD80; the disease is neoplasm.